Article Data

  • Views 501
  • Dowloads 119

Original Research

Open Access

Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer

  • M. Shimokawa1
  • M. Ohki1
  • T. Kaku1,*,

1Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

DOI: 10.12892/ejgo2643.2015 Vol.36,Issue 4,August 2015 pp.370-375

Published: 10 August 2015

*Corresponding Author(s): T. Kaku E-mail: kakut@med.kyushu-u.ac.jp

Abstract

Purpose of Investigation: The authors examined the relation between post-progression survival (PPS) and overall survival (OS) in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer. Materials and Methods: The authors partitioned OS into progression-free survival (PFS) and PPS and evaluated the relation between OS and either PFS or PPS. They also examined whether any association might be affected by the year of completion of trial enrollment. Results: The average PPS was longer in recent trials than in older trials (26.9 vs. 20.2 months, p = 0.0002). For all trials, PPS was strongly associated with OS (r = 0.94), whereas PFS was more moderately but still strongly correlated with OS (r = 0.83). The average proportion of median OS accounted for by median PPS significantly increased from 54.1% in older trials to 60.3% in recent trials (p = 0.0001). Conclusion: The present findings indicate that, especially for recent trials, PPS is more highly associated than PFS with OS in first-line chemotherapy for advanced epithelial ovarian cancer.

Keywords

Chemotherapy; Ovarian cancer; Overall survival; Progression-free survival; Phase III trial.

Cite and Share

M. Shimokawa,M. Ohki,T. Kaku. Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer. European Journal of Gynaecological Oncology. 2015. 36(4);370-375.

References

[1] Saad E.D., Katz A., Buyse M.: “Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials”. J. Clin. Oncol., 2010, 28, 1958.

[2] Hayashi H., Okamoto I., Morita S., Taguri M., Nakagawa K.: “Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer”. Ann. Oncol., 2012, 23, 1537.

[3] Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al.: “Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study”. J. Clin. Oncol., 2000, 18, 106.

[4] Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al.: “Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results”. J. Natl. Cancer Inst., 2000, 92, 699.

[5] Neijt J.P., Engelholm S.A., Tuxen M.K., Sorensen P.G., Hansen M., Sessa C., et al.: “Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer”. J. Clin. Oncol., 2000, 18, 3084.

[6] Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al.: “Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group”. J. Clin. Oncol., 2001, 19, 1001.

[7] Misset J.L., Vennin P., Chollet P.H., Pouillart P., Laplaige P.H., Frobert J.L., et al.: “Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients”. Ann. Oncol., 2001, 12, 1411.

[8] International Collaborative Ovarian Neoplasm Group: “Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial”. Lancet, 2002, 360, 505.

[9] Breitbach G.P., Meden H., Schmid H., Kühn W., Sass G., Schach S., et al.: “Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study”. Anticancer Res., 2002, 22, 2923.

[10] Dittrich C.H., Sevelda P., Salzer H., Obermair A., Speiser P,. Breitenecker G., et al.: “Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide- cisplatin”. Eur. J. Cancer, 2003, 39, 1129.

[11] Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al.: “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2003, 21, 3194.

[12] du Bois A., Lück H.J., Meier W., Adams H.P., Möbus V., Costa S., et al.: “A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer”. J. Natl. Cancer Inst., 2003, 95, 1320.

[13] Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al.: “Intraperitoneal cisplatin and paclitaxel in ovarian cancer”. N. Engl. J. Med., 2006, 354, 34.

[14] Reed N.S., Poole C.J., Coleman R., Parkin D., Graham J.D., Kaye S.B., et al.: “A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG)”. Eur. J. Cancer, 2006, 42, 179.

[15] du Bois A., Weber B., Rochon J., Meier W., Goupil A., Olbricht S., et al.: “Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens”. J. Clin. Oncol., 2006, 24, 1127.

[16] Pfisterer J., Weber B., Reuss A., Kimmig R., du Bois A., Wagner U., et al.: “Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO”. J. Natl. Cancer Inst., 2006, 98, 1036.

[17] Grénman S., Wiklund T., Jalkanen J., Kuoppala T., Mäenpää J., Kuronen A., et al.: “A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study”. Eur. J. Cancer, 2006, 42, 2196.

[18] Mouratidou D., Gennatas C., Michalaki V., Papadimitriou A., Andreadis C.H., Sykiotis C., Tsavaris N.: “A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer”. Anticancer Res., 2007, 27, 681.

[19] Möbus V., Wandt H., Frickhofen N., Bengala C., Champion K., Kimmig R., et al.: “Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT”. J. Clin. Oncol., 2007, 25, 4187.

[20] Spriggs D.R., Brady M.F., Vaccarello L., Clarke-Pearson D.L., Burger R.A., Mannel R., et al.: “Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2007, 25, 4466.

[21] Ray-Coquard I., Paraiso D., Guastalla J.P., Leduc B., Guichard F., Martin C., et al.: “Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group”. Br. J. Cancer, 2007, 97, 1200.

[22] Lhommé C., Joly F., Walker J.L., Lissoni A.A., Nicoletto M.O., Manikhas G.M., et al.: “Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer”. J. Clin. Oncol., 2008, 26, 2674.

[23] Aravantinos G., Fountzilas G., Bamias A., Grimani I., Rizos S., Kalofonos H.P., et al.: “Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study”. Eur. J. Cancer, 2008, 44, 2169.

[24] Bookman M.A., Brady M.F., McGuire W.P., Harper P.G., Alberts D.S., Friedlander M., et al.: “Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup”. J. Clin. Oncol., 2009, 27, 1419.

[25] Bookman M.A.: “GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma”. J. Clin. Oncol., 2006, ASCO Annual Meeting Proceedings.

[26] du Bois A., Herrstedt J., Hardy-Bessard A.C., Müller H.H., Harter P., Kristensen G., et al.: “Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer”. J. Clin. Oncol., 2010, 28, 4162.

[27] Gordon A.N., Teneriello M., Janicek M.F., Hines J., Lim P.C., Chen M.D., et al.: “Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer”. Gynecol. Oncol., 2011, 123, 479.

[28] Broglio K.R., Berry D.A.: “Detecting an overall survival benefit that is derived from progression-free survival”. J. Natl. Cancer Inst., 2009, 101, 1642.

[29] Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al.: “Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin”. J. Clin. Oncol., 1991, 9, 389.

[30] Harries M., Gore M.: “Part II: chemotherapy for epithelial ovarian cancer- treatment of recurrent disease”. Lancet Oncol., 2002, 3, 537.

[31] Buda A., Floriani I., Rossi R., Colombo N., Torri V., Conte P.F., et al.: “Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group”. Br. J. Cancer, 2004, 90, 2112.

[32] Sehouli J., Stengel D., Oskay-Oezcelik G., Zeimet A.G., Sommer H., Klare P., et al.: “Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group”. J. Clin. Oncol., 2008, 26, 3176.

[33] Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al.: “Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial”. Lancet, 2003, 361, 2099.

[34] Pfisterer J., Vergote I., Du Bois A., Eisenhauer E.: “Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer”. Int. J. Gynecol. Cancer, 2005, 15, 36.

[35] González-Martín A.J., Calvo E., Bover I., Rubio M.J., Arcusa A., Casado A., et al.: “Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study”. Ann. Oncol., 2005, 16, 749.

[36] Buyse M., Squifflet P., Laporte S., Fossella F., Georgoulias V., Pujol J., et al.: “Prediction of survival benefits from progression-free survival in patients with advanced non-small-cell lung cancer: evidence from a pooled analysis of 2,838 patients randomized in 7 trials”. J. Clin. Oncol., 2008, 26, 8019.

[37] Mauguen A., Michiels S., Burdett S., Tierney J., Sause W., Mandrekar S., et al.: “Evaluation of progression-free survival as a surrogate endpoint for overall survival when evaluating the effect of chemotherapy and radiotherapy in locally advanced lung cancer using data from four individual patient data meta-analyses”. J. Thorac. Oncol., 2011, 6, S464.

[38] Hotta K., Fujiwara Y., Matsuo K., Kiura K., Takigawa N., Tabata M., Tanimoto M.: “Time to progression as a surrogate marker for overall survival in patients with advanced non-small-cell lung cancer”. J. Thorac. Oncol., 2009, 4, 311.

[39] Johnson K.R., Ringland C., Stokes B.J., Anthony D.M., Freemantle N., Irs A., et al.: “Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis”. Lancet Oncol., 2006, 7, 741.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top